glioblastoma multiforme
Oncology · 2005–2010
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bevacizumab Treatment of patients with relapsed or progressing glioblastoma multiforme as monotherapy. | Nov 2010 | Not recommended | unclear |
| carmustine Recurrent glioblastoma multiforme (GBM) in patients for whom surgical resection is indicated and recurrence has occurred within 6 months of temozolomide or… | Jul 2008 | Not recommended | no section in document |
| carmustine Treatment of recurrent glioblastoma multiforme in patients for whom surgical resection is indicated. | Mar 2007 | Not recommended | no section in document |
| carmustine Newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. | Nov 2005 | Recommended with restriction | no section in document |
What the PBS pays
$49M in government benefit over 2024–25, across 78,306 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| bevacizumab | $49.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| carmustine implantsCarmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) | TA149 | terminated | 2008-06 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| temozolomideAPO-TEMOZOLOMIDE temozolomide 100 mg capsule bottle | 2009 | 54 |
| aminolevulinic acidALACARE 5-aminolevulinic acid hydrochloride 8 mg dermal patch sachet | 2013 | 2 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.